Verici Dx CEO Sara Barrington speaks at Edison Open House: Global Healthcare 2022

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalized patient and organ response risk to assist clinicians in medical management for improved patient outcomes.

  • Tell us about your patient-based focus in the area of kidney transplant.
  • Which research underpins your platform? • How does this open up treatment options?
  • What does the US designation of laboratory developed tests (LDT) mean for Clarava and Tuteva, and how does the commercialisation strategy differ in other markets?
  • Might the technology work for other types of organ transplant?
  • What are your licensing and intellectual property strategies?
  • Which milestones should investors focus on in the coming year?
en English
en Englishfr Frenchit Italianes Spanish
crossmenuchevron-down